Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Immunotherapy is a mainstay of non-small cell lung cancer (NSCLC) management. While
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …

Immunotherapy for metastatic colorectal cancer is effective only for mismatch repair-deficient
tumors with high microsatellite instability that demonstrate immune infiltration, suggesting …

Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 editing of
immune checkpoint genes could improve the efficacy of T cell therapy, but the first necessary …